These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38587211)

  • 21. Coptisine inhibits RANKL-induced NF-κB phosphorylation in osteoclast precursors and suppresses function through the regulation of RANKL and OPG gene expression in osteoblastic cells.
    Lee JW; Iwahashi A; Hasegawa S; Yonezawa T; Jeon WB; Cha BY; Nagai K; Woo JT
    J Nat Med; 2012 Jan; 66(1):8-16. PubMed ID: 21656335
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
    Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
    Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Specific RANK Cytoplasmic Motifs Drive Osteoclastogenesis.
    Li Y; Shi Z; Jules J; Chen S; Kesterson RA; Zhao D; Zhang P; Feng X
    J Bone Miner Res; 2019 Oct; 34(10):1938-1951. PubMed ID: 31173390
    [TBL] [Abstract][Full Text] [Related]  

  • 24. E-cadherin is important for cell differentiation during osteoclastogenesis.
    Fiorino C; Harrison RE
    Bone; 2016 May; 86():106-18. PubMed ID: 26959175
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhanced dual function of osteoclast precursors following calvarial Porphyromonas gingivalis infection.
    Cai X; Li Z; Zhao Y; Katz J; Michalek SM; Feng X; Li Y; Zhang P
    J Periodontal Res; 2020 Jun; 55(3):410-425. PubMed ID: 31944305
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification and characterization of the new osteoclast progenitor with macrophage phenotypes being able to differentiate into mature osteoclasts.
    Takeshita S; Kaji K; Kudo A
    J Bone Miner Res; 2000 Aug; 15(8):1477-88. PubMed ID: 10934646
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Zoledronic acid inhibits RANK expression and migration of osteoclast precursors during osteoclastogenesis.
    Kimachi K; Kajiya H; Nakayama S; Ikebe T; Okabe K
    Naunyn Schmiedebergs Arch Pharmacol; 2011 Mar; 383(3):297-308. PubMed ID: 21225243
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Docosahexaenoic acid signaling attenuates the proliferation and differentiation of bone marrow-derived osteoclast precursors and promotes apoptosis in mature osteoclasts.
    Kim HJ; Ohk B; Yoon HJ; Kang WY; Seong SJ; Kim SY; Yoon YR
    Cell Signal; 2017 Jan; 29():226-232. PubMed ID: 27836739
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stimulation of osteoclast formation by RANKL requires interferon regulatory factor-4 and is inhibited by simvastatin in a mouse model of bone loss.
    Nakashima Y; Haneji T
    PLoS One; 2013; 8(9):e72033. PubMed ID: 24039733
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SARS-CoV-2 Infection of Human Neurons Is TMPRSS2 Independent, Requires Endosomal Cell Entry, and Can Be Blocked by Inhibitors of Host Phosphoinositol-5 Kinase.
    Kettunen P; Lesnikova A; Räsänen N; Ojha R; Palmunen L; Laakso M; Lehtonen Š; Kuusisto J; Pietiläinen O; Saber SH; Joensuu M; Vapalahti OP; Koistinaho J; Rolova T; Balistreri G
    J Virol; 2023 Apr; 97(4):e0014423. PubMed ID: 37039676
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CCR2 Signaling Restricts SARS-CoV-2 Infection.
    Vanderheiden A; Thomas J; Soung AL; Davis-Gardner ME; Floyd K; Jin F; Cowan DA; Pellegrini K; Shi PY; Grakoui A; Klein RS; Bosinger SE; Kohlmeier JE; Menachery VD; Suthar MS
    mBio; 2021 Dec; 12(6):e0274921. PubMed ID: 34749524
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Infection of RANKL-primed RAW-D macrophages with Porphyromonas gingivalis promotes osteoclastogenesis in a TNF-α-independent manner.
    Kukita A; Ichigi Y; Takigawa I; Watanabe T; Kukita T; Miyamoto H
    PLoS One; 2012; 7(6):e38500. PubMed ID: 22723864
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SC-19220, antagonist of prostaglandin E2 receptor EP1, inhibits osteoclastogenesis by RANKL.
    Tsujisawa T; Inoue H; Nishihara T
    J Bone Miner Res; 2005 Jan; 20(1):15-22. PubMed ID: 15619665
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Kalkitoxin Reduces Osteoclast Formation and Resorption and Protects against Inflammatory Bone Loss.
    Li L; Yang M; Shrestha SK; Kim H; Gerwick WH; Soh Y
    Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33669069
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
    Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
    J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alisol-B, a novel phyto-steroid, suppresses the RANKL-induced osteoclast formation and prevents bone loss in mice.
    Lee JW; Kobayashi Y; Nakamichi Y; Udagawa N; Takahashi N; Im NK; Seo HJ; Jeon WB; Yonezawa T; Cha BY; Woo JT
    Biochem Pharmacol; 2010 Aug; 80(3):352-61. PubMed ID: 20412788
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MCP-1-induced human osteoclast-like cells are tartrate-resistant acid phosphatase, NFATc1, and calcitonin receptor-positive but require receptor activator of NFkappaB ligand for bone resorption.
    Kim MS; Day CJ; Selinger CI; Magno CL; Stephens SR; Morrison NA
    J Biol Chem; 2006 Jan; 281(2):1274-85. PubMed ID: 16280328
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-IFN-γ Antibody Promotes Osteoclastogenesis in Human Bone Marrow Monocyte-Derived Macrophages Co-Cultured with Tuberculosis-Activated Th1 Cells.
    Deng J; Sun D; Luo F; Zhang Q; Chen F; Xu J; Zhang Z
    Cell Physiol Biochem; 2018; 49(4):1512-1522. PubMed ID: 30205409
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interleukin-27 inhibits human osteoclastogenesis by abrogating RANKL-mediated induction of nuclear factor of activated T cells c1 and suppressing proximal RANK signaling.
    Kalliolias GD; Zhao B; Triantafyllopoulou A; Park-Min KH; Ivashkiv LB
    Arthritis Rheum; 2010 Feb; 62(2):402-13. PubMed ID: 20112358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.